Joanna
Joanna Albala, Stockton, CA US
Patent application number | Description | Published |
---|---|---|
20110188782 | Hand-Held Portable Microarray Reader For Biodetection - A hand-held portable microarray reader for biodetection includes a microarray reader engineered to be small enough for portable applications. The invention includes a high-powered light-emitting diode that emits excitation light, an excitation filter positioned to receive the excitation light, a slide, a slide holder assembly for positioning the slide to receive the excitation light from the excitation filter, an emission filter positioned to receive the excitation light from the slide, a lens positioned to receive the excitation light from the emission filter, and a CCD camera positioned to receive the excitation light from the lens. | 08-04-2011 |
Joanna Ashton-Chess, Nantes FR
Patent application number | Description | Published |
---|---|---|
20100104581 | Methods for Diagnosing and Treating Graft Rejection and Inflammatory Conditions - The present invention relates to a method of diagnosis and/or prognosis of an inflammatory condition, which method comprises determining the expression level of TRIB1 in a biological sample of a patient, in particular in peripheral blood or in a biopsy of a diseased tissue. Methods for treating inflammatory conditions by modulating TRIB1 expression or activity are also described. | 04-29-2010 |
20100305038 | DIAGNOSTIC OF IMMUNE GRAFT TOLERANCE USING TMTC3 GENE EXPRESSION LEVELS - The present invention concerns a method for the in vitro diagnosis or prognosis of a graft tolerant or graft non-tolerant phenotype, comprising: determining from a grafted subject biological sample an expression profile comprising TMTC3 gene, optionally measuring other parameters, and determining the presence of a graft tolerant or graft non-tolerant phenotype from said expression profile and optional other parameters, wherein said method does not comprise determining an expression profile comprising, in addition to TMTC3, the following 7 genes: BUB1B, CDC2, CHEK1, MS4A1, RAB30, RHOH, and SYNGR3. Said method may further comprise, if said subject is diagnosed as a graft non-tolerant subject, diagnosing from the expression profile if said subject is developing chronic rejection. The present invention also relates to a medicament comprising a TMTC3 protein, or a fragment, an analogue or an analogue fragment thereof, in particular for the treatment, prevention, delay or inhibition of graft rejection. | 12-02-2010 |
20110071071 | PSMB10: A DIAGNOSIS MARKER AND THERAPEUTIC TARGET OF CHRONIC REJECTION - The present invention relates to a method for diagnosing chronic graft rejection of a grafted organ in a subject from a biological sample of said subject, comprising: (a) determining in vitro an expression level value for PSMB10 in said subject biological sample, (b) comparing said value to at least one reference expression level value for PSMB10 in at least one reference sample, and (c) diagnosing if said subject is or not undergoing chronic rejection of said grafted organ. The invention also concerns a diagnostic kit or microarray for performing the method of the invention. The invention further concerns the medical use of proteasome inhibitors for treating chronic rejection. | 03-24-2011 |
Joanna Atman, Saugatuck, MI US
Patent application number | Description | Published |
---|---|---|
20120068512 | Arm assembly for a chair - An office chair is provided with includes a chair arm assembly on each opposite side thereof for supporting the arms of a user. The arm assemblies each include a latching assembly to permit adjustment of the height of an arm cap thereof while maintaining the arm cap at a selected elevation. The latch assembly is engageable with an inner liner provided within a support post. Further, the armrest assembly has a plurality of interconnected and relatively movable plates which permit adjustment of the angular orientation of the arm cap along with adjustment of the arm cap in the front-to-back direction and the side-to-side direction. | 03-22-2012 |
Joanna Bakala, Paris FR
Patent application number | Description | Published |
---|---|---|
20100129471 | ISO CA-4 AND ANALOGUES THEREOF AS POTENT CYTOTOXIC AGENTS INHIBITING TUBULINE POLYMERIZATION - The invention relates to a compound of the formula (I) in which: R | 05-27-2010 |
20110160228 | DIHYDRO-ISO-CA-4 AND ANALOGUES: POTENT CYTOTOXICS, INHIBITORS OF TUBULIN POLYMERIZATION - The present invention relates to compounds of formula (I) below in which: —R | 06-30-2011 |
20120252866 | Age Inhibitors - The invention relates to a compound having general formula I, wherein: X represents CH | 10-04-2012 |
Joanna Bereta, Krakow PL
Patent application number | Description | Published |
---|---|---|
20120164687 | NEW STRAIN OF SALMONELLA ENTERICA S. TYPHIMURIUM, ITS USE AND A METHOD TO OBTAIN A THERAPEUTIC VACCINE VECTOR - The present invention relates to a new bacterial strain of | 06-28-2012 |
Joanna Birch-Jones, Kent GB
Patent application number | Description | Published |
---|---|---|
20110318988 | TOY COMPRISING A FRUIT OR VEGETABLE SHAPED BODY AND AN AUDIO DEVICE - A toy is disclosed comprising a fruit or vegetable shaped body and an audio device configured to play a pre-recorded message, wherein the audio device is housed in a housing external to the toy and coupled to the toy. The audio device may be configured to play a pre-recorded message which recites the benefits of eating that particular fruit or vegetable. | 12-29-2011 |
Joanna Chorostowska-Wynimko, Warsaw PL
Patent application number | Description | Published |
---|---|---|
20100137209 | MODIFIED PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 AND METHODS BASED THEREON - The present invention is based upon the discovery that modified plasminogen activator inhibitor type-I (PAI-1) in which two or more amino acid residues that do not contain a sulfhydryl group have been replaced with amino acid residues that contain a sulfhydryl group and, therefore, forms intramolecular disulfide bonds, have increased in vivo half-life. Also disclosed are the modified PAI-1 proteins, derivatives and analogs thereof, specific antibodies, nucleic acid molecules and host cells. Methods for producing modified PAI-1, derivatives and analogs are also provided. The invention further relates to Therapeutics, pharmaceutical compositions and method of using the composition for treatment. The invention may be used to inhibit angiogenesis in a subject, thereby treating diseases or conditions associated with undesired angiogenesis and cell proliferation. Such conditions include psoriasis, chronic inflammation, tumor invasion and metastasis and conditions in which angiogenesis is pathogenic. The modified PAI-1 molecules of the present invention are useful for the treatment, prophylaxis, management and amelioration of cardiovascular diseases such as, but not limited to those that are related to hyperfibrinolysis, hemophilia, and vessel leakage syndrome. | 06-03-2010 |
Joanna Chwastowska, Tarnow PL
Patent application number | Description | Published |
---|---|---|
20120324334 | Collecting User Feedback about Web Pages - A user may desire to provide feedback on a web page displayed at a client. To collect feedback, a feedback module is provided to and executed at the client to provide feedback functionality. The feedback module creates a mask to prevent interaction with the original web page, clones the original web page, and displays a clone version in place of the masked original page. In addition, the feedback module creates an annotation frame to receive annotations of the clone version of the web page. A feedback report including a feedback image showing the clone version of the web page and the received annotations is generated by the module for submission to a server. | 12-20-2012 |
Joanna Dakes, Tucson, AZ US
Patent application number | Description | Published |
---|---|---|
20130060659 | SYSTEM AND METHOD FOR SPLITTING COLLABORATION ON EVENT METRICS FOR A SUPPLIER TO RESPOND TO BASED ON FUNCTIONAL ROLE - Embodiments of the invention relate to methods and systems of splitting collaboration on event metrics for a supplier to respond to based on functional role. The method includes establishing review groups. Each of the review groups includes at least one user. The method further includes associating bid factors to one or more of the review groups, displaying each of the bid factors in accordance with the association of the bid factors with each of the review groups, receiving rankings for each of the bid factors from each of the review groups associated with the bid factors, receiving answers to each of the bid factors from at least one supplier, ranking each of the answers to the bid factors. and correlating the rankings for each of the rankings of the bid factors and the rankings of the answers to generate a score for the at least one supplier. | 03-07-2013 |
Joanna Dojillo, San Diego, CA US
Patent application number | Description | Published |
---|---|---|
20110003736 | PESTICIDAL PROTEINS - The subject invention concerns new classes of pesticidally active proteins and the polynucleotide sequences that encode these proteins. In preferred embodiments, these pesticidal proteins have molecular weights of approximately 40-50 kDa and of approximately 10-15 kDa. | 01-06-2011 |
Joanna Duligall, Gloucestershire GB
Patent application number | Description | Published |
---|---|---|
20120039617 | PHOTONIC QUANTUM SYSTEM ALIGNMENT USING MULTIPLE BEAMS - A handheld device ( | 02-16-2012 |
20120120390 | BEAM DIRECTION SENSOR - A direction sensor ( | 05-17-2012 |
Joanna Duligall, Bristol GB
Patent application number | Description | Published |
---|---|---|
20100080394 | QKD transmitter and transmission method - In order to facilitate alignment of a QKD transmitter and QKD receiver, the transmitter is provided with a retro-reflector for returning to the receiver a photon beam originating at the latter. The transmitter is arranged to polarization modulate the retro-reflected beam. The transmitter is provided both with an intensity detector for generating an indication of retro-reflected photon intensity, and an intensity-dependent controller for controlling the QKD transmitter in dependence on the detected photon intensity. In one embodiment, this control involves aborting operation of the QKD transmitter upon an unexpectedly high photon intensity being detected; in another embodiment, the intensity indication is used to control the attenuation of the retro-reflected beam so as stabilize the average retro-reflected photon count per unit time. | 04-01-2010 |
Joanna Duligall, Gloucester GB
Patent application number | Description | Published |
---|---|---|
20090310784 | QKD System Alignment - QKD receiving apparatus is provided with an alignment-correction system for correcting misalignment of a quantum signal received at an optical port of the apparatus relative to a quantum-signal detector of the receiving apparatus. The alignment-correction system comprises a misalignment measuring subsystem for making multiple different misalignment measures, and a misalignment compensation subsystem for adjusting the relative alignment of the quantum signal and quantum-signal detector in dependence on the misalignment measures made. The misalignment measuring subsystem comprises an alignment-beam source, an alignment-beam detector arrangement, and optical components for guiding an alignment beam from the alignment-beam source to the optical port, and for guiding the alignment beam, after external retro-reflection at a cooperating QKD transmitting apparatus from the optical port to the alignment-beam detector arrangement. | 12-17-2009 |
Joanna Dziewiszek, Boxborough, MA US
Patent application number | Description | Published |
---|---|---|
20110196025 | Polymorphs of N-Malonyl-Bis(N'-Methyl-N'-Thiobenzoylhydrazide) - At least 70% by weight of Compound 1 is the single crystalline form, Form A, Form C, or Form D, of the compound. A pharmaceutical composition comprises a pharmaceutically acceptable carrier or diluent, and compound 1, wherein at least 70% by weight of the compound is the single crystalline form, Form A, Form C, or Form D, of the compound. A method of treating a subject with cancer comprises administering to the subject an effective amount of compound 1 or the pharmaceutical composition. | 08-11-2011 |
20140350115 | POLYMORPHS OF N-MALONYL-BIS(N`-METHYL-N`-THIOBENZOYLHYDRAZIDE) - At least 70% by weight of Compound 1 is the single crystalline form, Form A, Form C, or Form D, of the compound. A pharmaceutical composition comprises a pharmaceutically acceptable carrier or diluent, and compound 1, wherein at least 70% by weight of the compound is the single crystalline form, Form A, Form C, or Form D, of the compound. A method of treating a subject with cancer comprises administering to the subject an effective amount of compound 1 or the pharmaceutical composition. | 11-27-2014 |
Joanna Fare, Huddinge SE
Patent application number | Description | Published |
---|---|---|
20100043970 | METHOD OF PRODUCING A WOOD BASED PRODUCT - The present invention relates to a method of producing a wood based product comprising applying a water-based adhesive composition comprising non-gelatinised starch, the composition further comprises from 0.1 to 50 weight % of one or more polymers (P) containing an amine group or an amide group, onto one or more pieces of a wood-based material and joining the one or more pieces with one or more further pieces of a wood based material. | 02-25-2010 |
20120115992 | ADHESIVE SYSTEM AND METHOD OF PRODUCTING A WOOD BASED PRODUCT - The invention relates to an adhesive system comprising a protein; a polymer comprising at least one carboxylic group or at least one carboxylic anhydride group, or a combination thereof, with the proviso that said polymer does not contain 5 to 90 wt-% of vinyl pivalate units in combination with 0.2 to 15 wt-% of primary hydroxyl group-containing vinyl compound units, and a polyamine-epihalohydrin. The invention further relates to the use of the adhesive system, an adhesive composition, a method of producing a wood based product and a wood based product. | 05-10-2012 |
Joanna Fraczek, Gent BE
Patent application number | Description | Published |
---|---|---|
20100196929 | STABILISATION OF THE PHENOTYPIC PROPERTIES OF ISOLATED PRIMARY CELLS - The invention provides a method for stabilisation of phenotypic properties of isolated primary cells comprising modulating at least two epigenetic modifications in said cells. | 08-05-2010 |
20100278782 | DIFFERENTIATION OF RAT LIVER EPITHELIAL CELLS INTO HEPATOCYTE-LIKE CELLS - Methods for differentiation of cells of a rat liver epithelial (RLEC) cell line to hepatocyte-like cells are disclosed. In particular, methods involve sequential exposure of the RLEC to two or more differentiation agents. Cells obtained by the method are described as well as their uses in various pharmacological, toxicological, therapeutic, diagnostic and research applications. | 11-04-2010 |
Joanna Gajewiak, Salt Lake City, UT US
Patent application number | Description | Published |
---|---|---|
20100261681 | ALPHA-CHLORO AND ALPHA-BROMO PHOSPHONATE ANALOGS OF LYSOPHOSPHATIDIC ACID AND METHODS OF MAKING AND USING THEREOF - Described herein is the synthesis and pharmacology of a series of α-substituted methylene phosphonate analogs, in which the α-CH | 10-14-2010 |
Joanna Grudzinska, Bonn DE
Patent application number | Description | Published |
---|---|---|
20120237496 | PROTEASE VARIANTS - The present invention relates to polypeptides comprising protease variants of wild type human neprilysin having an altered specificity and/or activity. In particular the present invention relates to polypeptides comprising protease variants derived from human neprilysin having an increased specificity and/or activity against certain substrates, in particular against amyloid beta. | 09-20-2012 |
Joanna Grudzinska, Berlin DE
Patent application number | Description | Published |
---|---|---|
20120108796 | Optimized Monoclonal Antibodies against Tissue Factor Pathway Inhibitor (TFPI) - Isolated monoclonal antibodies that bind human tissue factor pathway inhibitor (TFPI) are provided. Isolated nucleic acid molecules encoding monoclonal antibodies that bind TFPI are also contemplated. Pharmaceutical compositions comprising the anti-TFPI monoclonal antibodies and methods of treating deficiencies or defects in coagulation by administration of the antibodies are also provided. Methods of producing the antibodies are also provided. | 05-03-2012 |
Joanna Grudzinska, Cologne DE
Patent application number | Description | Published |
---|---|---|
20120329996 | Optimized Monoclonal Antibodies against Tissue Factor Pathway Inhibitor (TFPI) - Isolated monoclonal antibodies that bind human tissue factor pathway inhibitor (TFPI) are provided. Isolated nucleic acid molecules encoding monoclonal antibodies that bind TFPI are also contemplated. Pharmaceutical compositions comprising the anti-TFPI monoclonal antibodies and methods of treating deficiencies or defects in coagulation by administration of the antibodies are also provided. Methods of producing the antibodies are also provided. | 12-27-2012 |
Joanna Grudzinska-Goebel, Berlin DE
Patent application number | Description | Published |
---|---|---|
20140050743 | BINDING PROTEINS TO INHIBITORS OF COAGULATION FACTORS - The present invention relates to the identification and use of antigen-binding regions, antibodies, antigen-binding antibody fragments and antibody mimetics, neutralizing the anti-coagulant effect of an anticoagulant in vitro and/or in vivo. Antibodies and functional fragments of the invention and antibody mimetics can be used to specifically reverse the pharmacological effect of an anticoagulant e.g. a FXa inhibitor for therapeutic (antidote) and/or diagnostic purposes. The invention also provides nucleic acid sequences encoding foregoing molecules, vectors containing the same, pharmaceutical compositions and kits with instructions for use. | 02-20-2014 |
Joanna Guzzetta, Portland, OR US
Patent application number | Description | Published |
---|---|---|
20100005717 | SYSTEM AND METHOD FOR POTTING PLANTS - Embodiments of a system and method for potting plants are disclosed. The system can include a drain shield, a filling material, and a liner for placing between the filling material and a growing medium. In particular embodiments, the filling material comprises expanded polystyrene spheres. The liner is a porous material allowing passage of fluids and preventing passage of substantial amounts of growing medium. The drain shield can include a top wall, at least two supports, at least two bottom walls, and a bottom member having a plurality of openings. The drain shield may include adhesive strips for securing the drain shield to a bottom wall of the container. Also disclosed are embodiments of a method for potting a plant in a container having at least one drain hole in a bottom wall of the container. | 01-14-2010 |
Joanna Hergovich Lisztwan, Walton-On-Thames GB
Patent application number | Description | Published |
---|---|---|
20120149661 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS - The invention relates to tetra-substituted heteroarylic compounds of the formula (I) | 06-14-2012 |
20130281473 | SUBSTITUTED ISOQUINOLINONES AND QUINAZOLINONES - The invention relates to substituted nitrogen containing bicyclic heterocycles of the formula (I) | 10-24-2013 |
Joanna Hergovich Lisztwan, Basel CH
Patent application number | Description | Published |
---|---|---|
20100125064 | 3-Imidazolyl-Indoles for the Treatment of Proliferative Diseases - The invention relates to 3-heterocyclyl indolyl compounds capable of inhibiting the interaction between p53, or variants thereof, and MDM2 and/or MDM4, or variants thereof, respectively, said compounds having the formula I, | 05-20-2010 |
20110230457 | Substituted Isoquinolinones and Quinazolinones - The invention relates to substituted nitrogen containing bicyclic heterocycles of the formula (I) | 09-22-2011 |
Joanna Iczkiewicz, London GB
Patent application number | Description | Published |
---|---|---|
20090137463 | Treatment for Neurodegeneration - Polypeptides which are an N- and/or C-terminally truncated fragment of the human osteopontin (hOPN) sequence or species variant, and which minimally have a 15 amino acid sequence corresponding to amino acids 138 to 152 of hOPN, and polynucleotides encoding said polypeptide, are useful for treatment or prevention of neurodegeneration. | 05-28-2009 |
Joanna Jakobkiewicz-Banecka, Gdansk PL
Patent application number | Description | Published |
---|---|---|
20090062380 | ISOFLAVONES FOR TREATING MUCOPOLYSACCHARIDOSES - The invention relates to the medical use of natural isoflavones and their semisynthetic derivatives or the pharmaceutically acceptable salts thereof for the therapeutic and/or prophylactic treatment of diseases, at the base of which lies an excessive production or storage of glycosaminoglycans, especially for treatment of mucopolysaccharidoses. The isoflavones and their semisynthetic derivatives are represented by formula (I), in which R | 03-05-2009 |
20120190642 | ISOFLAVONES FOR TREATING MUCOPOLYSACCHARIDOSES - A method of treatment of mucopolysaccharidosis, the method including administering to a patient in the need of such treatment—a therapeutically effective amount of a natural isoflavone of formula (I), a derivative thereof, or a pharmaceutically acceptable salt thereof. A pharmaceutical composition including a pharmaceutically acceptable excipient; and a natural isoflavone of formula (I), a derivative thereof, or a pharmaceutically acceptable salt thereof, the natural isoflavone, the derivative thereof, or the pharmaceutically acceptable salt thereof being in a therapeutically effective amount for the treatment of mucopolysaccharidosis. | 07-26-2012 |
20140107051 | ISOFLAVONES FOR TREATING MUCOPOLYSACCHARIDOSES - A pharmaceutical composition including a pharmaceutically acceptable excipient; and a natural isoflavone of formula (I), a derivative thereof, or a pharmaceutically acceptable salt thereof, the natural isoflavone, the derivative thereof, or the pharmaceutically acceptable salt thereof being in a therapeutically effective amount for the treatment of mucopolysaccharidosis. A method of treatment of mucopolysaccharidosis, the method including administering to a patient in the need of such treatment—a therapeutically effective amount of a natural isoflavone of formula (I), a derivative thereof, or a pharmaceutically acceptable salt thereof. | 04-17-2014 |
Joanna Jamontt, Hatfield GB
Patent application number | Description | Published |
---|---|---|
20100286098 | USE OF TETRAHYDROCANNABINOL AND/OR CANNABIDIOL FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE - The present invention relates to the use of a substantially pure tetrahydrocannabinol (THC) or a THC containing extract in which THC is a primary cannabinoid, in the manufacture of a medicament for use in the treatment of an inflammatory bowel disease. A further embodiment of the invention relates to the use of a substantially pure cannabidiol (CBD) or a CBD containing extract in which CBD is a primary cannabinoid, in the manufacture of a medicament for use in the treatment of an inflammatory bowel disease. Additionally the substantially pure cannabidiol (CBD) or a CBD containing extract in which CBD is a primary cannabinoid are used in the manufacture of a medicament for use as an adjunct therapy in the treatment of an inflammatory bowel disease. | 11-11-2010 |
Joanna Jusis, Lincoln Park, NJ US
Patent application number | Description | Published |
---|---|---|
20090197952 | Glyceride Esters for the Treatment of Diseases Associated with Reduced Neuronal Metabolism of Glucose - Provided are alternative sources of ketone bodies for reducing or eliminating symptoms of Parkinson's disease, amyotrophic lateral sclerosis (ALS, also called Lou Gehrig's disease), Alzheimer's disease, Huntington's disease, epilepsy and other diseases or disorders characterized by impaired glucose metabolism. The alternative sources of ketone bodies include mono-, di- and triglyceride esters of acetoacetate and mixtures thereof, and/or mono-, di- and triglyceride esters of 3-hydroxybutyrate and mixtures thereof. These glyceride esters can be administered orally as a dietary supplement or in a nutritional composition. | 08-06-2009 |
Joanna Karasiewicz, Komorniki PL
Patent application number | Description | Published |
---|---|---|
20120157703 | SYNTHESIS OF FLUOROSILICONES AND THEIR DERIVATIVES - The subject of invention is the method of synthesis of fluorosilicone co-polymers of arbitrary topology and general formula 1 in which among others if A stands for CH—O(CH | 06-21-2012 |
20120165565 | SYNTHESIS OF FLUOROCARBOFUNCTIONAL ALKOXYSILANES AND CHLOROSILANES - The subject of invention is the method of synthesis of fluorocarbofunctional alkoxysilanes and chlorosilanes of the general formula HCF | 06-28-2012 |
Joanna Keep, Hertfordshire GB
Patent application number | Description | Published |
---|---|---|
20110051713 | FACSIMILE PRIORITIZATION WITHIN INTERNET PROTOCOL CALL NETWORKS - A method and apparatus maintain a facsimile number priority hierarchy within a computer storage medium and process a first facsimile call being transmitted through a computerized call processor. The first facsimile call is made between a first telephone number associated with the computerized call processor and a second telephone number not associated with the computerized call processor. While processing the first facsimile call, the computerized call processor receives an indication of an attempt to connect a second facsimile call between the first telephone number and a third telephone number. The third telephone number is not associated with the computerized call processor. The method and apparatus determine a priority between the second telephone number and the third telephone number based on the facsimile number priority hierarchy. If the second telephone number has a higher priority than the third telephone number, the computerized call processor does not connect the second facsimile call. However, if the third telephone number has a higher priority than the second telephone number, the computerized call processor terminates the first facsimile call and connects the second facsimile call by connecting the third telephone number to the first telephone number. | 03-03-2011 |
20120200898 | FACSIMILE SERVICE SUPPORT DEVICE, SYSTEM, AND METHOD - An exemplary method herein operates to help diagnose and correct facsimile transmission errors. The method detects a first facsimile transmission error using an arbitrarily named “first” facsimile machine (which can be a sending facsimile machine or a receiving facsimile machine). The facsimile transmission error occurs during a first facsimile transmission sent from the sending facsimile machine to the receiving facsimile machine. Upon detecting the first facsimile transmission error, the sending facsimile machine automatically contacts a service center computer. The service center computer automatically connects the sending facsimile machine to the receiving facsimile machine through the service center computer. Then, the sending facsimile machine sends a test facsimile transmission to the receiving facsimile machine through the service center computer. The method automatically records sounds sent by the sending facsimile machine and the receiving facsimile machine using the service center computer to produce an audio diagnostic file and automatically forwards the audio diagnostic file to a service engineer for diagnosis. | 08-09-2012 |
Joanna Keep, Stevenage GB
Patent application number | Description | Published |
---|---|---|
20110273747 | APPARATUS AND METHOD FOR FACSIMILE TRANSMISSION CONFIGURATION - An apparatus and method that configures a facsimile transmission protocol for a facsimile device is disclosed. The method can include transmitting an echo request via a network connection to a facsimile device. The method can include receiving a response to the echo request via the network connection from the facsimile device. The method can include determining network throughput impairments based on the received response to the echo request. The method can include adjusting a facsimile transmission protocol based on the determined network throughput impairments. The method can include transmitting a facsimile message based on the adjusted facsimile transmission protocol. | 11-10-2011 |
20110296498 | Fax authentication for secure fax transmission and of unwanted faxes - A system and a method of authenticating faxes are disclosed. The method includes receiving image data that includes at least one page to be transmitted by a sending fax device. An authentication code is generated at the sending fax device. The authentication code is transmitted to a receiving fax device. The receiving fax device determines whether the authentication code is one which is accepted. If it is, the receiving fax device authorizes commencement of the fax transmission. | 12-01-2011 |
Joanna Klein Nagel Voort, Zwolle NL
Patent application number | Description | Published |
---|---|---|
20100040814 | RESIN COMPOSITION SUITABLE FOR (RE) LINING OF TUBES, TANKS AND VESSELS - The present invention relates to structural, radically curable resin compositions suitable for (re)lining containing a. 30-70 wt. % of a resin characterized by (i) a molecular weight M | 02-18-2010 |
Joanna Kowalska, Radom PL
Patent application number | Description | Published |
---|---|---|
20100233757 | Synthesis and Use of Anti-Reverse Phosphorothioate Analogs of the Messenger RNA Cap - New RNA cap analogs are disclosed containing one or more phosphorothioates groups. The analogs also contain modifications at the 2′-O position of 7-methylguanosine that prevent them from being incorporated in the reverse orientation during in vitro synthesis of mRNA and that hence are “anti-reverse cap analogs” (ARCAs). The ARCA modification ensures that the S atom is precisely positioned within the active sites of cap-binding proteins in both the translational and decapping machinery. The new S-ARCA analogs are resistant to in vivo decapping enzymes. Some S-ARCAs have a higher affinity for eIF4E than the corresponding analogs not containing a phosphorothioate group. When mRNAs containing the various S-ARCAs are introduced into cultured cells, some are translated as much as five-fold more efficiently than mRNAs synthesized with the conventional analog m | 09-16-2010 |
20110092574 | mRNA Cap Analogs - Dinucleotide cap analogs are disclosed, modified at different phosphate positions with a boranophosphate group or a phosphoroselenoate group. The analogs are useful as reagents in the preparation of capped mRNAs and have increased stability both in vitro and in vivo. They may be used as inhibitors of cap-dependent translation. Optionally, the boranophosphate or phosphoroselenoate group has a 2′-O or 3′-O-alkyl group, preferably a methyl group, producing analogs called BH | 04-21-2011 |
20120195917 | Vaccine Composition Comprising 5'-CAP Modified RNA - The present invention relates to modification of RNA with 5′-cap analogs in order to improve the stability and increase the expression of said RNA, in particular in immature antigen presenting cells. The present invention provides a vaccine composition comprising said stabilized RNA, immature antigen presenting cells comprising said stabilized RNA, and methods for stimulating and/or activating immune effector cells and for inducing an immune response in an individual using said stabilized RNA. | 08-02-2012 |
Joanna Kubler-Kielb, Bethesda, MD US
Patent application number | Description | Published |
---|---|---|
20100150954 | VACCINES AGAINST INFLUENZA VIRUS - Disclosed are immunogenic conjugates having the general formula: | 06-17-2010 |
20100158937 | METHODS FOR CONJUGATION OF OLIGOSACCHARIDES OR POLYSACCHARIDES TO PROTEIN CARRIERS THROUGH OXIME LINKAGES VIA 3-DEOXY-D-MANNO-OCTULSONIC ACID - Methods for preparing an oligosaccharide-protein carrier immunogenic conjugate or a polysaccharide-protein carrier immunogenic conjugate. The methods include obtaining an oligosaccharide or polysaccharide having a KDO moiety located at the terminal reducing end of the oligosaccharide or polysaccharide that includes a carbonyl functional group; and reacting the carbonyl functional group of the KDO moiety with an aminooxylated protein carrier molecule resulting in a conjugate that includes a covalent oxime bond between the oligosaccharide and the protein carrier or the polysaccharide and the protein carrier. | 06-24-2010 |
20100183678 | CONJUGATES OF PLASMODIUM FALCIPARUM SURFACE PROTEINS AS MALARIA VACCINES - Conjugates of ookinete surface protein Pfs25 are provided that are efficacious as vaccines against | 07-22-2010 |
20100330074 | USE OF SACCHARIDES CROSS-REACTIVE WITH BACILLUS ANTHRACIS SPORE GLYCOPROTEIN AS A VACCINE AGAINST ANTHRAX - Provided are immunogenic compositions and methods for eliciting an immune response against | 12-30-2010 |
20110182929 | MULTICOMPONENT VACCINE FOR MALARIA PROVIDING LONG-LASTING IMMUNE RESPONSES AGAINST PLASMODIA - Disclosed are immunogenic conjugates which elicit an immune response to | 07-28-2011 |
20110212125 | VACCINE FOR SHIGELLA - Disclosed are immunogenic conjugates and therapeutic compositions that include such immunogenic conjugates. Also disclosed are methods of treating and/or inhibiting an | 09-01-2011 |
20110223163 | MONOCLONAL ANTIBODIES THAT REACT WITH THE CAPSULE OF BACILLUS ANTHRACIS - The present disclosure relates to monoclonal antibodies that bind poly-γ-D-glutamic acid (γDPGA), which is present on the surface of | 09-15-2011 |
20130129777 | CONJUGATES OF PLASMODIUM FALCIPARUM SURFACE PROTEINS AS MALARIA VACCINES - Conjugates of ookinete surface protein Pfs25 are provided that are efficacious as vaccines against | 05-23-2013 |
20130216570 | MULTICOMPONENT VACCINE FOR MALARIA PROVIDING LONG-LASTING IMMUNE RESPONSES AGAINST PLASMODIA - Disclosed are immunogenic conjugates which elicit an immune response to | 08-22-2013 |
20130273097 | USE OF SACCHARIDES CROSS-REACTIVE WITH BACILLUS ANTHRACIS SPORE GLYCOPROTEIN AS A VACCINE AGAINST ANTHRAX - Provided are immunogenic compositions and methods for eliciting an immune response against | 10-17-2013 |
20130287787 | MONOCLONAL ANTIBODIES THAT REACT WITH THE CAPSULE OF BACILLUS ANTHRACIS - The present disclosure relates to monoclonal antibodies that bind poly-γ-D-glutamic acid (γDPGA), which is present on the surface of | 10-31-2013 |
20140205622 | VACCINES AGAINST INFLUENZA VIRUS - Disclosed are immunogenic conjugates having the general formula: | 07-24-2014 |
20140234360 | INFLUENZA VACCINE - Disclosed are immunogenic conjugates having the general formula: HA2-XXX-Pr, where HA2 is the influenza HA2 fusion peptide or a portion thereof, XXX is a linker and Pr is the carrier. Methods of producing an immune response in a subject using the disclosed immunogenic conjugates, as well as methods of treating, ameliorating or preventing influenza infection, are also disclosed. | 08-21-2014 |
20140242666 | VACCINE FOR SHIGELLA - Disclosed are immunogenic conjugates and therapeutic compositions that include such immunogenic conjugates. Also disclosed are methods of treating and/or inhibiting an | 08-28-2014 |
20140378669 | METHODS FOR CONJUGATION OF OLIGOSACCHARIDES OR POLYSACCHARIDES TO PROTEIN CARRIERS THROUGH OXIME LINKAGES VIA 3-DEOXY-D-MANNO-OCTULSONIC ACID - Methods for preparing an oligosaccharide—protein carrier immunogenic conjugate or a polysaccharide—protein carrier immunogenic conjugate. The methods include obtaining an oligosaccharide or polysaccharide having a KDO moiety located at the terminal reducing end of the oligosaccharide or polysaccharide that includes a carbonyl functional group; and reacting the carbonyl functional group of the KDO moiety with an aminooxylated protein carrier molecule resulting in a conjugate that includes a covalent oxime bond between the oligosaccharide and the protein carrier or the polysaccharide and the protein carrier. | 12-25-2014 |
20150050314 | CONJUGATES OF PLASMODIUM FALCIPARUM SURFACE PROTEINS AS MALARIA VACCINES - Conjugates of ookinete surface protein Pfs25 are provided that are efficacious as vaccines against | 02-19-2015 |
Joanna Kubler-Kielb, Rockville, MD US
Patent application number | Description | Published |
---|---|---|
20100040644 | METHODS FOR PREPARING IMMUNOGENIC CONJUGATES - Methods for making an immunogenic conjugate that includes a hapten or an antigen covalently linked to a carrier. The methods include reacting a first agent with a dihydrazide resulting in a hydrazine-modified first agent, wherein the first agent is a hapten, an antigen or a carrier; reacting a second agent with a benzaldehyde compound resulting in a benzaldehyde-modified second agent, wherein the second agent is a hapten, an antigen or a carrier, provided that the first agent or the second agent is a carrier; and reacting the hydrazine-modified first agent with the benzaldehyde-modified second agent resulting in an immunogenic conjugate comprising a hapten or an antigen covalently linked to a carrier via a hydrazone linkage. | 02-18-2010 |
20100062023 | CHOLESTEROL-CONTAINING COMPOUNDS AND THEIR USE AS IMMUNOGENS AGAINST BORRELIA BURGDORFERI - Unique compounds that can be used for inducing an immune response to | 03-11-2010 |
Joanna Lai, Santa Clara, CA US
Patent application number | Description | Published |
---|---|---|
20100184276 | LOW-TEMPERATURE FORMATION OF POLYCRYSTALLINE SEMICONDUCTOR FILMS VIA ENHANCED METAL-INDUCED CRYSTALLIZATION - A method for forming polycrystalline semiconductor film from amorphous semiconductor film at reduced temperatures and/or accelerated rates. The inclusion of a small percentage of semiconductor material, such as 2% within the metal layer, reduces the temperatures required for crystallization of the amorphous semiconductor by at least 50° C. in comparison to the use of the metal layer without the small percentage of semiconductor material. During a low temperature isothermal annealing process adjacent Al-2% Si and a-Si films undergo a layer exchange resulting in formation of a continuous polycrystalline silicon film having good physical and electrical properties. Formation of polycrystalline-semiconductor in this manner is suitable for use with low temperature substrates (e.g., glass, plastic) as well as with numerous integrated circuit and MEMs fabrication devices and practices. | 07-22-2010 |
Joanna Lignelli, Baltimore, MD US
Patent application number | Description | Published |
---|---|---|
20080268987 | MOLDED LACROSSE HEAD POCKET - A pocket for a head of a lacrosse stick is provided that includes a plurality of runners extending generally in a longitudinal direction and a plurality of cross laces extending generally in a transverse direction. The pocket further includes one or more joint members that are formed at an intersection of a runner and a cross lace. The runner and the cross lace lie over one another and are held in place by the joint member. A method for forming the pocket is also disclosed. | 10-30-2008 |
20120264551 | HANDLE-DAMPENING LACROSSE STICK - A lacrosse stick for reducing the rebound of a ball caught therein. The head of the lacrosse stick is affixed to a tubular shaft in which a portion of the shaft wall at the top end is omitted on the front side and another portion is omitted on the backside below the first omitted portion. A resilient member is inserted within the shaft extending past the lower omitted portion of the shaft wall. The resilient member fills the omitted areas to seat flush therein. A head having a socket and throat is affixed to top end of the shaft. The socket engages the resilient insert via the omitted portions. When a force is applied, for example, by a ball caught in the pocket, the socket compresses the resilient member from the front and the throat from the back allowing the head to rotate backward, dissipating some of the energy and reducing rebound. | 10-18-2012 |
20130244816 | HANDLE-DAMPENING LACROSSE STICK - A lacrosse stick for reducing the rebound of a ball caught therein. The head of the lacrosse stick has a socket for receiving the shaft, and incorporates one or a plurality of flexible elastomer pads within or as part of the handle or socket, where the head and handle meet, to damp impact and rebound. The flexibility of the damping pads produces a “give” that minimizes the rebound of a pocket after being impacted by a ball. This pocket dampening limits the movement of the ball and makes the ball easier to control and to retain in the pocket. The precise location of the dampening material on the lacrosse head may be varied to control the degree of pocket “give” in response to, for example, the force on the pocket created by a ball impacting the pocket during a catch or swinging in the pocket during cradling. | 09-19-2013 |
Joanna Livadas, Millbrae, CA US
Patent application number | Description | Published |
---|---|---|
20140058855 | SYSTEM AND METHOD FOR MOBILE AND SOCIAL CUSTOMER RELATIONSHIP MANAGEMENT - Methods and systems for facilitating electronic transactions using one or more computer based devices and remote requests and authorizations for funding proposed transactions for products or services. | 02-27-2014 |
Joanna Lubas, Fremont, CA US
Patent application number | Description | Published |
---|---|---|
20080269868 | STENT DELIVERY CATHETER SYSTEM AND METHOD OF IMPLANTING A SELF-EXPANDING STENT WITH EMBOLIC PROTECTION - A catheter system and method for implanting an i such as a stent at a treatment site in a patient's body lumen. The catheter provides a complete system for stent delivery, dilatation, and delivery and/or recovery of an expandable device, such as an embolic protection device, adjacent to the treatment site in the body lumen. | 10-30-2008 |
20100331951 | STENT DELIVERY CATHETER SYSTEM AND METHOD OF IMPLANTING A SELF-EXPANDING STENT WITH EMBOLIC PROTECTION - A catheter system and method for implanting an endoprosthesis such as a stent at a treatment site in a patient's body lumen. The catheter provides a complete system for stent delivery, dilatation, and delivery and/or recovery of an expandable device, such as an embolic protection device, adjacent to the treatment site in the body lumen. | 12-30-2010 |
Joanna Mamrowicz, Lesko PL
Patent application number | Description | Published |
---|---|---|
20110284103 | ACCESSING A VALVE ASSEMBLY OF A TURBOMACHINE - An example method of accessing a valve assembly of a turbomachine includes accessing a check valve of the valve assembly from a first position that is radially outside a flow path through the turbomachine. The method accessing a shut off valve of the valve assembly from a second position that is radially outside the flow path. The check valve and the shut off valve are configured to influence communication of lubricant along a lubricant communication path that extends between a location radially outboard the flow path and a location radially inboard the flow path. The first position is the same as the second position in some examples. | 11-24-2011 |
Joanna Marguier, Lausanne CH
Patent application number | Description | Published |
---|---|---|
20120099788 | METHOD AND APPARATUS FOR SELECTING A COLOR PALETTE - A method for selecting a color palette includes receiving a feature from an image of an object and a reference color chart, calculating a transform to correct a color in the imaged reference color chart, correcting a color in the feature using the transform, and selecting a color palette based on the corrected feature color. The reference color chart includes reference colors, and the transform corrects the color in the imaged reference color chart to substantially equal a corresponding reference color. An apparatus for selecting a color palette is also described. | 04-26-2012 |
Joanna Matyjasik, Denatrion PL
Patent application number | Description | Published |
---|---|---|
20110105342 | METHOD FOR DETERMINING REDUCED PREDISPOSITION TO CANCER BASED ON GENETIC PROFILE - The invention provide methods for early detection of a reduced risk of developing cancer, which comprises detecting the absence of a series of genetic polymorphisms associated with a predisposition of developing cancer, including the polymorphisms of the genes BRCA1, BRCA2, CARD15 (NOD2), CHEK2, CDKN2A (P16), CYP1B1, FGFR2 (KGFR2), MAP3K1 (MEKK1), p53 (TP53), TNRC9, XPD (ERCC2) and the genetic marker Rs6983267, in a biological sample from the analyzed subject, wherein the absence of the genetic polymorphisms is indicative of significantly decreased risk of developing, at least, breast cancer. | 05-05-2011 |
Joanna Mecfel-Marczewski, Altenmarkt An Der Alz DE
Patent application number | Description | Published |
---|---|---|
20110313177 | 2-Oxo-1, 3-dioxolane-4-carboxylic Acid and Derivatives Thereof, Their Preparation and Use - 2-Oxo-1,3-dioxolane-4-carboxylic acid and derivatives thereof, according to the following formula, | 12-22-2011 |
Joanna Mecfel-Marczewski, Tacherting DE
Patent application number | Description | Published |
---|---|---|
20120316286 | Water Dispersable, Cyclic-Carbonate-Functionalized Vinyl Copolymer System - A water-dispersible, cyclocarbonate-functionalized vinyl copolymer binder, a process for the preparation of the binder, an aqueous dispersion containing the binder, a system comprising the binder, water and an (amine) curing agent and the use of the binder for the production of a hardened coating are proposed. | 12-13-2012 |
Joanna Misiti, Hermosa Beach, CA US
Patent application number | Description | Published |
---|---|---|
20120253308 | ARTICLE INCLUDING VISUAL SIGNAL FOR COMMUNICATION OF A FUNCTIONAL BENEFIT - The present invention provides an absorbent article including a longitudinally extending a top surface, a cover layer, a barrier layer, an absorbent core arranged between the cover layer and the barrier layer, a printed portion, a plurality of non-printed portions, wherein the printed portion and the plurality of non-printed portions are arranged to create a perception of a functional benefit by a user looking upon the top surface of the absorbent article. | 10-04-2012 |
Joanna Norstroem, Basel CH
Patent application number | Description | Published |
---|---|---|
20110160730 | Osteosynthesis Plate for Treatment of Fractures or Osteotomies in the Vicinity of Joints - The osteosynthesis plate according to the invention comprises at least two legs, which are spaced apart and interconnected by at least one bridge element. The legs each have a certain length and extend in the longitudinal direction from an epiphyseal to a diaphyseal end of the osteosynthesis plate. Moreover, both legs each comprise at least one opening for holding an anchoring element. The size and shape of the at least one bridge element and the at least two legs are configured such that the legs may be applied on both sides of a bone in the region of a joint, preferably on the olecranon. | 06-30-2011 |
Joanna Oat, Ledyard, CT US
Patent application number | Description | Published |
---|---|---|
20110252557 | SOIL SOLIDIFIER AND RELATED METHODS - A method for constructing a structure, preferably a swimming pool, includes the steps of excavating a cavity, applying a sub-base such as sand along at least a portion of the cavity, forming the sub-base into the desired shape of the structure, and applying a solidifier solution to the sub-base. The solidifier solution comprises a polymer in solution. The solidifier solution and the sub-base harden to form a smooth, hard composite layer in the base of the cavity, with the composite layer containing at least some of the polymer and at least some of the sub-base in a polymer lattice. After the solidifier solution has been applied, a liner may be installed, and the swimming pool may be filled. | 10-20-2011 |
20110257314 | SOIL SOLIDIFIER AND RELATED METHODS - A method for constructing a structure, preferably a swimming pool, includes the steps of excavating a cavity, applying a sub-base such as sand along at least a portion of the cavity, forming the sub-base into the desired shape of the structure, and applying a solidifier solution to the sub-base. The solidifier solution comprises a polymer in solution. The solidifier solution and the sub-base harden to form a smooth, hard composite layer in the base of the cavity, with the composite layer containing at least some of the polymer and at least some of the sub-base in a polymer lattice. After the solidifier solution has been applied, a liner may be installed, and the swimming pool may be filled. Additionally, the solidifier solution may be applied directly to the cavity, or to masonry or other materials, and may be used to construct any applicable structure. | 10-20-2011 |
Joanna Röder, Steamboat Springs, CO US
Patent application number | Description | Published |
---|---|---|
20120193525 | Predictive test for selection of metastatic breast cancer patients for hormonal and combination therapy - A mass-spectral method is disclosed for determining whether a breast cancer patient is likely to benefit from administration of a combination treatment in the form of a targeted anti-cancer drug in addition to an endocrine therapy drug. The method obtains a mass spectrum from a blood-based sample from the patient. The spectrum is subject to one or more predefined pre-processing steps. Values of selected features in the spectrum at one or more predefined m/z ranges are obtained. The values are used in a classification algorithm using a training set comprising class-labeled spectra a class label for the sample is obtained. If the class label is “Poor”, the patient is identified as being likely to benefit from the combination treatment. In a variation, the “Poor” class label predicts whether the patient is unlikely to benefit from endocrine therapy drugs alone, regardless of the patient's HER2 status. | 08-02-2012 |
Joanna Röder, Steamboat Springs, CO US
Patent application number | Description | Published |
---|---|---|
20130131996 | Predictive Test for Selection of Metastatic Breast Cancer Patients for Hormonal and Combination Therapry - A mass-spectral method is disclosed for determining whether breast cancer patient is likely to benefit from a combination treatment in the form of administration of a targeted anti-cancer drug in addition to an endocrine therapy drug. The method obtains a mass spectrum from a blood-based sample from the patient. The spectrum is subject to one or more predefined pre-processing steps. Values of selected features in the spectrum at one or more predefined m/z ranges are obtained. The values are used in a classification algorithm using a training set comprising class-labeled spectra and a class label for the sample is obtained. If the class label is “Poor”, the patient is identified as being likely to benefit from the combination treatment. In a variation, the “Poor” class label predicts whether the patient is unlikely to benefit from endocrine therapy drugs alone, regardless of the patient's HER2 status. | 05-23-2013 |
20130344111 | Mass-Spectral Method for Selection, and De-Selection, of Cancer Patients for Treatment with Immune Response Generating Therapies - A method and system for predicting in advance of treatment whether a cancer patient is likely, or not likely, to obtain benefit from administration of a yeast-based immune response generating therapy, which may be yeast-based immunotherapy for mutated Ras-based cancer, alone or in combination with another anti-cancer therapy. The method uses mass spectrometry of a blood-derived patient sample and a computer configured as a classifier using a training set of class-labeled spectra from other cancer patients that either benefitted or did not benefit from an immune response generating therapy alone or in combination with another anti-cancer therapy. Also disclosed are methods of treatment of a cancer patient, comprising administering a yeast-based immune response generating therapy, which may be yeast-based immunotherapy for mutated Ras-based cancer, to a patient selected by a test in accordance with predictive mass spectral methods disclosed herein, in which the class label for the spectra indicates the patient is likely to benefit from the yeast-based immunotherapy. | 12-26-2013 |
20140012514 | Method for predicting whether a cancer patient will not benefit from platinum-based chemotherapy agents - A testing method for identification whether a cancer patient is a member of a group or class of cancer patients that are not likely to benefit from administration of a platinum-based chemotherapy agent, e.g., cisplatin, carboplatin or analogs thereof, either alone or in combination with other non-platinum chemotherapy agents, e.g., gemcitabine and paclitaxel. This identification can be made in advance of treatment. The method uses a mass spectrometer obtaining a mass spectrum of a blood-based sample from the patient, and a computer operating as a classifier and using a stored training set comprising class-labeled spectra from other cancer patients. | 01-09-2014 |
20140200825 | Method for predicting whether a cancer patient will not benefit from platinum-based chemotherapy agents - A testing method for identification whether a cancer patient is a member of a group or class of cancer patients that are not likely to benefit from administration of a platinum-based chemotherapy agent, e.g., cisplatin, carboplatin or analogs thereof, either alone or in combination with other non-platinum chemotherapy agents, e.g., gemcitabine and paclitaxel. This identification can be made in advance of treatment. The method uses a mass spectrometer obtaining a mass spectrum of a blood-based sample from the patient, and a computer operating as a classifier and using a stored training set comprising class-labeled spectra from other cancer patients. | 07-17-2014 |
Joanna Romanowska, Lubon PL
Patent application number | Description | Published |
---|---|---|
20130316970 | NUCLEOTIDE ANALOGUE, METHOD OF SYNTHESIS OF NUCLEOTIDE ANALOGUE, USE OF NUCLEOTIDE ANALOGUE, ANTIVIRAL PRO-NUCLEOTIDE, PHARMACEUTICAL COMPOSITION - The object of the invention are nucleotide analogues, antiviral pro-nucleotides, a use of nucleotide analogues and pharmaceutical composition, a phosphorylating agent for synthesis of nucleotide analogue, and a method of synthesis of nucleotide analogue. More precisely, the invention applies to the new group of nucleotide analogues and their use in partial or complete inhibition of human immunodeficiency virus (HIV). | 11-28-2013 |
Joanna Stoinska, Poznan PL
Patent application number | Description | Published |
---|---|---|
20140004232 | NANOIRON-BASED OXYGEN SCAVENGERS | 01-02-2014 |
Joanna Sweetgall, Allendale, NJ US
Patent application number | Description | Published |
---|---|---|
20110104017 | PORTABLE UV WATER TREATMENT SYSTEM - A portable water purification system and method of operation of the system is disclosed that may comprise a container defining a water purification chamber; a plurality of UV generating light sources distributed in the purification chamber of the container; and a portable power source electrically connected to the light sources, and adapted to convert kinetic energy to electrical energy to provide to the light sources. The portable power source may be adapted to be driven by human motive power to provide the kinetic energy. The purification system may comprise a filling opening to the container; and a filter intermediate the filling opening and the chamber adapted to remove turbidity from the water entering the water purification chamber through the filling opening. The portable power source may comprise a hand-cranked electrical generator. The UV light sources may produce UV light in a wavelength band selected to effectively deactivate all harmful biological water contaminants, and produce UV light in a dosage sufficient to effectively deactivate all harmful biological water contaminants. | 05-05-2011 |
Joanna Szewczyk, Mielec PL
Patent application number | Description | Published |
---|---|---|
20120213478 | OPTICAL FIBER CONNECTOR - An optical fiber connector includes a housing with at least one elongated cylindrical cavity, a fiber holder within the cavity including a ferrule which secures an optical fiber therein and a biasing member engaging the fiber holder to bias the ferrule towards an unmated position. A resilient metal latch is mounted on the housing for releasably securing the optical fiber connector to another component. A latch travel limiting structure prevents the latch from deflecting outside a desired predetermined path. Improved structures for mounting the latch on the housing and for creating a duplex connector assembly are also provided. | 08-23-2012 |
Joanna Szpunar, Lons FR
Patent application number | Description | Published |
---|---|---|
20090014640 | Nebulizer with Nanometric Flow Rate of a Liquid Effluent and Nebulizing Installation Comprising Same - The invention concerns a nebuliser with nanometric flow rate of a liquid effluent in a nebulising gas comprising at least arranged substantially concentric, a capillary tube for intake of the liquid effluent and a nebulising needle including a central channel fed with liquid effluent through the capillary tube, a chamber for intake of the nebulising gas feeding a nozzle for expelling the nebulising gas, the nebulising needle passing through the intake chamber and the nozzle expelling the nebulising gas, the nebulising needle including a outlet for the liquid effluent whereof the aperture diameter is less than 20 ?m, the ratio of the diameter of the outlet of the nozzle expelling the nebulising gas and the outlet of the nebulising needle being more than 10 The inventive nanometric flow rate nebuliser and nebulising installation are applicable in mass spectrometry of trace elements contained in intracellular or microbiological medium for example. | 01-15-2009 |
Joanna Tobien, Glienicke/nordbahn DE
Patent application number | Description | Published |
---|---|---|
20080248486 | Type Pept1 Protein Assay - The present invention relates to a type PepT1 protein assay and in particular a process for identifying a substrate and/or a modulator of the PepT1 protein. | 10-09-2008 |
Joanna Vlahopoulou, Newcastle Upon Tyne GB
Patent application number | Description | Published |
---|---|---|
20100206079 | ULTRASONIC MONITOR FOR A BIOREACTOR - A method and apparatus for monitoring the state of a microbiological or animal cell culture, or other bioprocess wherein the attenuation and in some embodiments, the speed of an ultrasonic wave passed through the culture is used to determine viscous and viscoelastic properties of the culture medium. | 08-19-2010 |
Joanna Wasyluk, Dresden DE
Patent application number | Description | Published |
---|---|---|
20130203244 | METHODS FOR PFET FABRICATION USING APM SOLUTIONS - A method for fabricating an integrated circuit is disclosed that includes, in accordance with an embodiment, providing an integrated circuit comprising a p-type field effect transistor (pFET), recessing a surface region of the pFET using an ammonia-hydrogen peroxide-water (APM) solution to form a recessed pFET surface region, and depositing a silicon-based material channel on the recessed pFET surface region. | 08-08-2013 |
20130203245 | METHODS FOR PFET FABRICATION USING APM SOLUTIONS - A method for fabricating an integrated circuit from a semiconductor substrate having formed thereon over a first portion of the semiconductor substrate a hard mask layer and having formed thereon over a second portion of the semiconductor substrate an oxide layer. The first portion and the second portion are electrically isolated by a shallow trench isolation feature. The method includes removing the oxide layer from over the second portion and recessing the surface region of the second portion by applying an ammonia-hydrogen peroxide-water (APM) solution to form a recessed surface region. The APM solution is provided in a concentration of ammonium to hydrogen peroxide ranging from about 1:1 to about 1:0.001 and in a concentration of ammonium to water ranging from about 1:1 to about 1:20. The method further includes epitaxially growing a silicon-germanium (SiGe) layer on the recessed surface region. | 08-08-2013 |
20130299874 | TMAH RECESS FOR SILICON GERMANIUM IN POSITIVE CHANNEL REGION FOR CMOS DEVICE - CMOS devices are enhanced by forming a recess in the positive channel for depositing SiGe. Embodiments include providing a positive channel region and a negative channel region in a silicon substrate for a CMOS device, with an STI region therebetween; removing a native oxide from above the positive channel region to expose a silicon substrate; forming a recess in the silicon substrate in the positive channel region adjacent the STI region; and depositing SiGe in the recess in the positive channel region, where an upper surface of the SiGe is substantially level with an upper surface of the negative channel region. | 11-14-2013 |
20130302973 | HORIZONTAL EPITAXY FURNACE FOR CHANNEL SIGE FORMATION - A method and apparatus are provided for recessing a channel region of the PFET and epitaxially growing channel SiGe in the recessed region inside of a horizontally oriented processing furnace. Embodiments include forming an n-channel region and a p-channel region in a front side of a wafer and at least one additional wafer, the n-channel and p-channel regions corresponding to locations for forming an NFET and a PFET, respectively; placing the wafers inside a horizontally oriented furnace having a top surface and a bottom surface, with the wafers oriented vertically between the top and bottom surfaces; recessing the p-channel regions of the wafers inside the furnace; and epitaxially growing cSiGe without hole defects in the recessed p-channel regions inside the furnace. | 11-14-2013 |
20140051227 | METHODS OF FORMING ISOLATION STRUCTURES FOR SEMICONDUCTOR DEVICES BY PERFORMING A DRY CHEMICAL REMOVAL PROCESS - A method includes forming a patterned mask comprised of a polish stop layer positioned above a protection layer above a substrate, performing at least one etching process through the patterned mask layer on the substrate to define a trench in the substrate, and forming a layer of silicon dioxide above the patterned mask layer such that the layer of silicon dioxide overfills the trench. The method also includes removing portions of the layer of silicon dioxide positioned outside of the trench to define an isolation structure, performing a dry, selective chemical oxide etching process that removes silicon dioxide selectively relative to the material of the polish stop layer to reduce an overall height of the isolation structure, and performing a selective wet etching process to remove the polish stop layer selectively relative to the isolation region. | 02-20-2014 |
20140187051 | Poly Removal for replacement gate with an APM mixture - A method for removing poly-silicon dummy gate structures using an ammonium hydroxide-hydrogen peroxide-water (APM) solution with concentrations between 1:10:20 and 1:1:2 and at temperatures between 20 C and 80 C for times between 1 minute and 60 minutes. | 07-03-2014 |
20150076560 | INTEGRATED CIRCUITS INCLUDING EPITAXIALLY GROWN STRAIN-INDUCING FILLS DOPED WITH BORON FOR IMPROVED ROBUSTNESS FROM DELIMINATION AND METHODS FOR FABRICATING THE SAME - Integrated circuits and methods for fabricating integrated circuits are provided. In one example, a method for fabricating an integrated circuit includes forming a cavity in a semiconductor region laterally adjacent to a gate electrode structure. An EPI strain-inducing fill is deposited into the cavity. The EPI strain-inducing fill includes a main SiGe layer and a Si cap that overlies the main SiGe layer. The EPI strain-inducing fill is doped with boron and has a first peak boron content in an upper portion of the EPI strain-inducing fill of about 2.5 times or greater than an average boron content in an intermediate portion of the main SiGe layer. | 03-19-2015 |
Joanna Wawrzyczek, Krakow PL
Patent application number | Description | Published |
---|---|---|
20140122453 | METHOD AND SYSTEM FOR REDUCING LOCK OCCURRENCES IN SERVER/DATABASE SYSTEMS - The invention relates to a computer-implemented method for limiting the number of concurrent requests in a database system including the following steps: arranging requests to be handled by the database system in at least one queue; defining a maximum value (SS) of concurrent requests corresponding to the at least one queue; monitoring at least one queue utilization parameter corresponding to the at least one queue and calculating a performance value based on the at least one queue utilization parameter, adapting the maximum value (SS) of concurrent requests of the at least one queue dynamically based on the performance value (PF) in order to improve system performance and limiting the number of concurrent requests of the at least one queue dynamically based on the dynamically adapted maximum value (SS). | 05-01-2014 |
20140372397 | REDUCING LOCK OCCURRENCES IN SERVER/DATABASE SYSTEMS - Limiting the number of concurrent requests in a database system. Arranging requests to be handled by the database system in at least one queue. Defining a maximum value (SS) of concurrent requests corresponding to the at least one queue. Monitoring at least one queue utilization parameter corresponding to the at least one queue and calculating a performance value based on the at least one queue utilization parameter. Adapting the maximum value (SS) of concurrent requests of the at least one queue dynamically based on the performance value (PF) in order to improve system performance. Limiting the number of concurrent requests of the at least one queue dynamically based on the dynamically adapted maximum value (SS). | 12-18-2014 |
Joanna Weidenmiller, San Francisco, CA US
Patent application number | Description | Published |
---|---|---|
20130339101 | REQUEST FOR PROPOSAL AUTHORING - Techniques and mechanisms described herein may facilitate the creation of a request for proposals. In some embodiments, user input for creating a document representing a request for proposals for a business action may be received. The user input may include information characterizing the business action. Suggested content to include in the document representing the request for proposals may be based on the received user input. The suggested content may describe the business action. The document representing the request for proposals may be created based on the received user input and the identified suggested content. The document may identify a business need and one or more criteria for responding to the request for proposals. The request for proposals may be stored on a storage medium. | 12-19-2013 |
20130339268 | SYSTEM AND METHOD FOR CREATION AND DISTRIBUTION OF PROPOSALS FOR ACTION - Techniques and mechanisms described herein facilitate the creation and distribution of proposals for action. According to various embodiments, input information corresponding with each of a plurality of sections to include in a proposal for action may be identified. At least a portion of the input information may be received via a communications interface. Output information to include in the proposal for action may be determined. The output information may be determined at least in part based on the identified input information. A document representing the proposal for action may be created. The created document may include the output information. The created document may be stored on a storage system. | 12-19-2013 |
Joanna Wencel, Cesson-Sevigne FR
Patent application number | Description | Published |
---|---|---|
20100267956 | CHIRAL TRIDENTATE COMPOUNDS, CORRESPONDING ORGANOMETAL COMPLEXES, METHOD FOR PREPARING SAME AND USE OF SAID COMPOUNDS AND COMPLEXES AS LIGANDS IN ASYMMETRICAL CATALYSIS - The invention relates to a compound of the formula (I) or the formula (II) in which: W is an oxygen atom or a radical of the formula NH; X is hydrogen or an alkaline cation or a C1-C8 alkyl or a —(CH | 10-21-2010 |
Joanna Wietrzyk, Wroclaw PL
Patent application number | Description | Published |
---|---|---|
20090264510 | Double helical oligonucleotides interfering with mRNA used as effective anticancer agents - The present invention relates to the application of double-helical oligonucleotides (siRNA) interfering with the mRNA of gene involved in carcinogenesis, particularly the Wnt1, Wnt2 or Her3 genes. Such oligonucleotides may be modified chemically, used in conjunction with viral and non-viral vectors such as lipid complexes. Such oligonucleotides exhibit unusual anti-proliferative properties against tumour cells and may be used in anti-tumour treatment. | 10-22-2009 |
20110245466 | METHOD OF PRODUCTION OF POLYANIONIC DRUG-CARRIER CONJUGATES - The invention concerns the method of production of a polyanionic macromolecule which is a protein built, among others, form polar amino acids (such as lysine, arginine, aspartic acid, glutamic acid), characteristic in that, that as a result of the reaction between amine groups and the cyclic anhydride of dicarboxylic acid, the charge changes towards more negatively charged carrier. This reaction gives rise to better therapeutic properties of macromolecules modified in this way. | 10-06-2011 |
20120101057 | COMBINED THERAPY OF COLORECTAL CARCINOMA - The invention relates to a combined therapy, wherein addition of a vitamin D analogue to the standard treatment regimen based on cytostatics, 5-fluorouracil and/or its precursors, generates potential possibility of achieving beneficial therapeutic effect in the first-line chemotherapy or adjuvant therapy of colorectal carcinoma. Vitamin D analogues are selected from a group consisting of tacalcitol, calcipotriol and 5,6-trans-isomer of calcipotriol. | 04-26-2012 |
20140031357 | ASYMMETRICALLY SUBSTITUTED ANTHRAPYRIDAZONE DERIVATIVES AS CYTOSTATICS - The invention relates to the new, asymmetrically substituted derivatives of 2,7-dihydro-3H-dibenzo[de,h]cinnoline-3,7-dione and their use as cytostatics exhibiting activity against tumor cells, especially against cells with multidrug resistance (MDR). In particular, the invention concerns derivatives of 2,7-dihydro-3H-dibenzo[de,h]cinnoline-3,7-dione represented by the general formula (I). | 01-30-2014 |
Joanna Wiszniewska, Houston, TX US
Patent application number | Description | Published |
---|---|---|
20130324431 | OLFACTORY RECEPTOR COPY NUMBER ASSOCIATION WITH AGE AT ONSET OF ALZHEIMER'S DISEASE - The present invention concerns determination of risk for an early age of onset for Alzheimer's Disease in an individual. In specific embodiments, it concerns identification of copy number at chromosome 14q11.2 or a region thereof and associating a high copy number with an earlier age of onset of Alzheimer's Disease. | 12-05-2013 |
Joanna Wojtalik, Victoria AU
Patent application number | Description | Published |
---|---|---|
20080308430 | Packaging for a Disposable Item - Packaging ( | 12-18-2008 |
Joanna Woodcock, Crafers West AU
Patent application number | Description | Published |
---|---|---|
20130231305 | Method of Modulating Protein 14-3-3 Functionality By Facilitating or Inhibiting Phosphorylation - The present invention relates to a method of modulating cellular activity. More particularly, the present invention provides a method of modulating apoptosis by modulating protein 14-3-3 phosphorylation and, thereby its functionality. The present invention still further extends to methods for identifying agents capable of modulating protein 14-3-3 phosphorylation. The method and molecules of the present invention are useful, inter alia, in the treatment and/or prophylaxis of conditions characterized by unwanted cellular activity, such as unwanted cell survival. | 09-05-2013 |
Joanna Zagrodzka, Warszawa PL
Patent application number | Description | Published |
---|---|---|
20090105483 | PROCESS FOR THE PREPARATION OF PRAMIPEXOLE BASE AND/OR ITS SALTS - The process for the preparation of pramipexole base and/or its pharmaceutically acceptable salts, especially the hydrochloride salt, in the alkylation reaction of (S)-(−)2,6-diamino-4,5,6,7-tetrahydrobenzothiazole with an alkylating agent, wherein the reaction is carried out in the absence of a base, and in a solvent from which the resulting N-monoalkylated product selectively precipitates out as a salt. After isolation from the reaction mixture, the N-monoalkylated product is converted a) into the free pramipexole base upon treatment with an inorganic base and is then converted into another pharmaceutically acceptable pramipexole salt; or b) directly into another pharmaceutically acceptable pramipexole salt or the hydrate thereof. | 04-23-2009 |
20110065922 | Process for Preparation Of Solifenacin and/or the Pharmaceutically Acceptable Salts Thereof of High Pharmaceutical Purity - A process for the preparation of solifenacin and/or the pharmaceutically acceptable salts thereof of high pharmaceutical purity is characterized in that 3-(R)-quinuclidinoloxy anion generated in situ from 3-(R)-quinuclidinol in a presence of strong base in polar organic solvent is subject to acylation with (S)-1-phenyl-1,2,3,4-tetrahydroisoquinolinecarbonyl chloride of chemical purity at least 98%, while maintaining constant anion excess in a reaction mixture, and after reaction completion solifenacin base is optionally transformed into solifenacin salt according to standard procedures. (S)-1-Phenyl-1,2,3,4-tetrahydroisoquinolinecarbonyl chloride of chemical purity at least 98% is obtained in a reaction of (S)-1-phenyl-1,2,3,4-tetrahydroisoquinoline and molar excess of phosgene in a presence of tertiary aromatic amine in aromatic hydrocarbon, and isolated in a crystalline form. | 03-17-2011 |
20110077405 | PROCESS FOR PREPARATION OF ENANTIOMERICALLY PURE (S)-1-PHENYI-1,2,3,4- TETRAHYDROISOQUINOLINE - Process for preparation of (S)-1-phenyl-1,2,3,4-tetrahydroisoquinoline wherein 1-phenyl-1,2,3,4-tetrahydroisoquinoline is reacted with D-(−)-tartaric acid in a solvent system comprising of methanol and water, preferably at 3.3:1 to 1:1 volume ratio, the crystallization mixture is left for crystallization and (S)-1-phenyl-1,2,3,4-tetrahydroisoquinoline is released from obtained crystalline diastereoisomeric salt according to standard procedures. (S)-1-Phenyl-1,2,3,4-tetrahydroisoquinoline is the intermediate in enantiomeric synthesis of solifenacin. | 03-31-2011 |
Joanna Zuberek, Warsaw PL
Patent application number | Description | Published |
---|---|---|
20110092574 | mRNA Cap Analogs - Dinucleotide cap analogs are disclosed, modified at different phosphate positions with a boranophosphate group or a phosphoroselenoate group. The analogs are useful as reagents in the preparation of capped mRNAs and have increased stability both in vitro and in vivo. They may be used as inhibitors of cap-dependent translation. Optionally, the boranophosphate or phosphoroselenoate group has a 2′-O or 3′-O-alkyl group, preferably a methyl group, producing analogs called BH | 04-21-2011 |